T
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Tom Menzies' research focuses on the statistical analysis of multiple myeloma patient data, particularly concerning treatment outcomes and prognostic factors. His work has investigated the significance of minimal residual disease after autologous stem-cell transplant and the impact of lenalidomide maintenance therapy. Menzies has also explored sex differences in multiple myeloma biology and clinical outcomes, analyzing data from large patient cohorts such as the Myeloma XI Trial.
His publications address optimal durations for lenalidomide maintenance and the incidence of second primary malignancies in patients receiving this treatment. Menzies' research also includes evaluating the addition of other agents, like vorinostat, to treatment regimens and examining clinical characteristics of specific myeloma subtypes, such as IgD myeloma. He has also contributed to methodological research, including comparisons of aggregation functions in multi-criteria decision analysis for drug benefit-risk assessment.
Metrics
- h-index: 8
- Publications: 20
- Citations: 259
Selected Publications
-
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry (2023)
Collaboration Network
Top Collaborators
David A. Cairns
Leeds Teaching Hospitals NHS Trust (GB)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Faith E. Davies
Leeds Teaching Hospitals NHS Trust (GB)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Mark T. Drayson
University Hospitals Birmingham NHS Foundation Trust (GB)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Martin Kaiser
University of Birmingham (GB)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Roger G. Owen
Institute of Cancer Research (CA)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Graham Jackson
University of Birmingham (GB)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Charlotte Pawlyn
Institute of Cancer Research (CA)
14 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 14 shared publications
Gordon Cook
University of Birmingham (GB)
13 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 13 shared publications
Gareth J. Morgan
University of Birmingham (GB)
13 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 13 shared publications
Matthew Jenner
University Hospital Southampton NHS Foundation Trust (GB)
9 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
Showing 5 of 9 shared publications
Walter M. Gregory
Cancer Research UK Clinical Trials Unit (GB)
8 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
- Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
Showing 5 of 8 shared publications
John R Jones
King's College Hospital (GB)
6 shared publications
- Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
- OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
- Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients
Showing 5 of 6 shared publications
Anna Hockaday
Leeds Trinity University (GB)
4 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
- Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
- OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
Rowena Henderson
University of Leeds (GB)
4 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk
- Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients
John R. Jones
University of Sussex (GB)
4 shared publications
- Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
- Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
- Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
- The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
Similar Researchers
Based on overlapping research topics
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Frits Vanrhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Abdul Rafae
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Munawwar Hussain
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Jaskirat S Sethi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Kristin Kampevold Larsen
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology